A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients
- 1 February 2006
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 118 (2-3) , 188-194
- https://doi.org/10.1016/j.clim.2005.10.002
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individualsClinical Immunology, 2005
- Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responsesClinical Immunology, 2005
- Diversity and Recognition Efficiency of T Cell Responses to CancerPLoS Medicine, 2004
- Phenotypic heterogeneity of antigen‐specific CD4 T cells under different conditions of antigen persistence and antigen loadEuropean Journal of Immunology, 2004
- Immunodominant CD4 + responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvantProceedings of the National Academy of Sciences, 2004
- Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantationBlood, 2003
- Survey of naturally occurring CD4 + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responsesProceedings of the National Academy of Sciences, 2003
- NY-ESO-1 and CTp11 Expression May Correlate with Stage of Progression in MelanomaJournal of Surgical Research, 2001
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991